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1. INTRODUCTION 
 
Essential thrombocythaemia (ET), characterized by the excessive proliferation of 
megakaryocytes in the bone-marrow and the overproduction of circulating platelets in the 
peripherial blood, which was was first recognized as a distinct clinical syndrome by Emil 
Epstein and Alfred Godelin in 1934, and in 1951 was listed as one of the classical 
myeloproliferative neoplasms (MPNs) in the classification by William Dameshek 1-3.  
As ET is characterized by proliferation of the megakaryocytic lineage without 
significant expansion of the granulocytic and erythroid lineages, the bone-marrow biopsy 
result frequently reveals a hypercellularity picture with an increased number of enlarged 
hyperlobated, mature megakaryocytes, without notably increased marrow fibrosis 4. The 
peripheral blood smear in many cases demonstrates enhanced numbers of platelets and 
megakaryocyte fragments 4, 5. In the initial phase of the disease, many patients are 
symptomless and the diagnosis is commonly established only fortuitously via a routine blood 
count. An elevated peripheral platelet count is indicative of the diagnosis of ET if the 
sustained value is ≥ 450 giga/L and other evidence of reactive thrombocytosis, such as 
infection, inflammation and other chronic myeloid neoplasms or lymphoproliferative 
disorders, is excluded 5. There are cases in which the presence of thrombohaemorrhagic 
events draw attention to ET as the underlying disease.  
It has been reported that the most important complications that can exert major effects 
on the morbidity and mortality of ET patients are thrombohaemorrhagic events, the risk of 
which approximately ranges between 11-25%  6-8. The risk of microvascular (e.g. headaches, 
dizziness, visual disturbances, distal paraesthesia, acrocyanosis, and erythromelalgia) and 
major thrombotic complications (e.g. arterial events: myocardial infarction (MI), ischaemic 
stroke or a transient ischaemic attack (TIA); venous events: deep venous thrombosis) is higher 
than the risk of haemorrhagic complications 6, 9.  
The ET-related haemostatic abnormalities and the pathogenesis of the major 
thrombotic complications or microvascular disturbances seen in ET still pose many questions, 
and in recent years this topic has been actively investigated 6, 10. It is currently suggested that 
not merely the elevated platelet count in the periphery itself, but this together with the 
consequent qualitative abnormalities of the platelets and other possible additional thrombotic 
risk factors (e.g. cardiovascular risk factors, leukocytosis and the JAK2 V617F, MPL and 
CALR mutations may influence the thrombotic complications seen in ET 6, 11-18.  
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The current haematological management strategy in ET is based on thrombosis risk-
oriented recommendations: patients classified as at low risk (age <60 years, without prior 
thrombotic event) receive anti-platelet therapy (e.g.: aspirin) if necessary, while high-risk 
patients (age >60 years and/or with a prior thrombotic event) receive cytoreductive drugs  
(e.g.: hydroxyurea) alone or in combination with anti-platelet therapy 19, 20. The roles of the 
JAK2 V617F mutation and other suggested thrombosis risk factors (e.g. cardiovascular risk 
factors) have not yet been integrated into this currently used risk stratification. However, for 
more accurate thrombosis risk-guided management, other thrombotic risk factors too should 
be taken into account. In 2012, Barbui et al. published the idea of a new score system, IPSET 
(International Prognostic Score of Thrombosis for ET) 14. The IPSET score includes a 
consideration of the predictive potential of the JAK2 V617F mutation and the cardiovascular 
risk factors (i.e.: high blood pressure, diabetes and active tobacco use). Furthermore, instead 
of merely the classical high- and low-risk group stratification, it introduces a three-subgroup 
(IPSET low-risk, IPSET intermediate-risk and IPSET high-risk) stratification model 14. 
Although this score system appears more promising than the conventional two-categorical 
risk assessment, and may promote a better prediction of major thrombotic complications in 
ET, it requires confirmation through investigations at more clinical centres. 
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2. AIMS 
 
The aim of the current Ph.D work was to create a retrospective study cohort of patients 
diagnosed with ET at the 2nd Department of Internal Medicine, University of Szeged, 
between 1999 and 2014, and to evaluate and analyse the following aspects: 
 
I. the occurrence of thrombotic events previously and in the follow-up period; 
 
II.    the role of the leukocyte count at the haematological diagnosis as a suggested, but     
              still controversial additional risk factor in the subsequent thrombotic complications; 
 
III.   the presence of JAK2 V617F, MPL mutations (W515L, W515K, W515R, W515A, 
S505N) and CALR (type-1 and type-2) mutations and their clinicohaematological role;  
 
IV.   the contributions of the main cardiovascular risk factors present at the time of the   
              haematological diagnosis of ET as suggested additional risk factors in the subsequent    
              thrombotic complications; 
 
V.   the main neurological and cardiological thrombotic complications from detailed   
 clinical aspects as the most important major thrombotic complications of ET, and  
 whether there are any special characteristics in the everyday clinical practice which  
 could predict the development of these complications or whether any typical   
 neurological or cardiological lesion may be identified which might be specific or  
 characteristic of ET; 
 
VI.   the clinical value of the recently introduced IPSET model as regards the  
       thrombosis-free survival of the patients. 
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3. METHODS 
 
3.1. PATIENTS AND DATA COLLECTION 
Retrospectively, we established an MPN database for scientific research, including the 
cases of ET diagnosed at the 2nd Department of Internal Medicine, University of Szeged. In 
2011, a basic database (“database 99-11”) was established on patients diagnosed between 
1999 and 2011. In 2014, a new enlarged database was created (“database 99-14”), in which 
patients diagnosed between January 1999 and July 2014 were enrolled. The main 
demographic and clinicohaematological characteristics of the study populations are presented 
in Table 1. 
Database 99-11 was used to evaluate the contributions of the main cardiovascular risk 
factors and the leukocyte count at the time of the haematological diagnosis of ET in the 
subsequent thrombotic complications, and for a detailed neurological analysis, laboratory 
testing and the evaluation of clinicohaematological role of the JAK2 V617F, MPL and CALR 
mutations. Database 99-14 served as the basis of detailed cardiological analyses and an 
evaluation of the clinical utility of the IPSET model as concerns the thrombosis-free survival 
of the patients. 
 This current scientific research was conducted with the approval of the Regional and 
Institutional Human Medical Biological Research Ethics Committee and adhered to the 
Declaration of Helsinki. Informed consent was not required. Patient DNA for genetic analyses 
of the JAK2 V617F, MPL and CALR mutations was selected from the DNA bank at the 
Institute of Medical Genetics, University of Szeged. Through use of the clinical centre data 
files (MedSol system), all the haematological results on these patients were reviewed. The 
thrombotic events before and after the clinical diagnosis of ET were retrospectively compiled 
for each patient, with special focus on cardiovascular (MI), cerebrovascular (stroke or a TIA) 
and venous thrombotic events (deep venous thrombosis or pulmonary embolism). The 
retrospective analysis of the thrombotic events in the cohort in database 99-11 revealed 38 
prior vascular events in 33 (32.67%) patients: 11 cerebrovascular events (stroke/TIA), 16 
cardiovascular events (MI) and 11 venous thrombotic events. During the haematological 
follow-up after the diagnosis of ET, 16 events were observed in 15 (14.85%) patients: 10 
cerebrovascular events (stroke/TIA), 3 cardiovascular events (MI) and 3 venous thrombotic 
events.  
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The enlarged database 99-14 finally revealed 55 prior vascular events in 47 (30.32%) 
patients: 22 cerebrovascular events (stroke/TIA), 17 cardiovascular events (MI) and 16 
venous thrombotic events. During the haematological follow-up after the diagnosis of ET, 25 
events were observed in 23 (14.83%) patients: 13 cerebrovascular events (stroke/TIA), 7 
cardiovascular events (MI) and 5 venous thrombotic events.  
Data on cardiovascular risk factors present at the time of the clinical diagnosis of ET, 
i.e. hypertension (> 140/80 mmHg), tobacco use, diabetes mellitus, hyperlipidaemia 
(hypercholesterolaemia or hypertriglyceridaemia or both), and obesity (body mass index 
(BMI) > 30 kg/m2) were collected.  Information relating to an inherited thrombophilic state 
was reported in only one case when lipoprotein A was diagnosed. In one patient ticlopidine- 
induced thrombotic thrombocytopenic purpura had developed (with a 78 giga/L platelet count 
at diagnosis), which drew attention to the underlying ET. 
In general, the haematological management strategy was based on risk-oriented 
recommendations: low-risk patients received anti-platelet therapy (e.g. aspirin) if necessary, 
while high-risk patients were given cytoreductive drugs (e.g. hydroxyurea) alone or in 
combination with anti-platelet therapy 7, 19, 20.  
 
3.2. STATISTICAL ANALYSES 
Clinical and data for genetic analyses were compiled with Microsoft Office Excel, and 
subjected to statistical analysis with Statsoft Statistica v 9.1 (Statsoft) and SPSS 20 software 
(IBM).  
Evaluation of the contribution of the leukocyte count 
To analyse the possible contribution of the leukocyte count (measured at the time of 
ET haematological diagnosis) in the prediction of subsequent thrombotic complications, a 
current patient population-related cut-off value based on bivariate binary logistic regression 
was first calculated. Optimum regression was used to find the cut-off value of the leukocyte 
count which had the most balanced predictive value. Mann–Whitney and multivariate binary 
logistic regression tests were performed in the cases of the presence or absence of thrombotic 
complications with the following variables: (a) the calculated leukocyte count cut-off related 
to the current population, and (b) leukocytosis with a median leukocyte count of at least 11.1 
giga/L. For a detailed prudent analysis, the presence of prior thrombotic events, an age over 
60, the JAK2 V617F mutation, the presence of at least one cardiovascular risk factor and the 
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applied therapy (hydroxyurea or aspirin) as suggested important variables were incorporated 
in the multivariate binary logistic regression analyses and their effects were considered in its 
result. To evaluate the probability of the thrombosis-free survival of patients at different 
leukocyte counts (as introduced above), the Kaplan–Meier method was used, followed by the 
log-rank test (Mantel–Cox) 21. Statistical significance was set at 5% and 10%. 
 
Evaluation of the clinicohaematological role of the JAK2 V617F mutation 
The Mann–Whitney test was performed in the case of the JAK2 V617F mutation- 
positive and negative patients in order to compare the overall effects of series of variables: (a) 
all thrombotic events after the clinical diagnosis of ET, and their subtypes: cardiovascular 
(MI), cerebrovascular (TIA or stroke) or venous thrombotic events (deep venous thrombosis 
or pulmonary embolism); (b) age; and (c) the main clinical characteristics: median white 
blood cell count; median platelet count; median haemoglobin count; median red blood cell 
count; hepatomegaly; splenomegaly and hepatosplenomegaly. Multivariate binary logistic 
regression analyses were performed to estimate the probability of thrombotic events in the 
presence of the JAK2 V617F mutation, and in this context, the conventional risk factors were 
also involved in the statistical model. By means of  the Kaplan–Meier method, followed by 
the log-rank test (Mantel–Cox), the probability of thrombosis-free survival was analysed and 
compared in four subgroups: (a) the JAK2 V617F(+), low-risk patients, (b) the JAK2 
V617F(+) high-risk patients, (c) the JAK2 V617F(-) low-risk patients, and (d) the JAK2 
V617F(-) high-risk patients 21. The low-risk patients were those aged < 60 years without any 
prior thrombotic event, while the patients in the high-risk category were those aged > 60 years 
and/or with a prior thrombotic event 19, 20. Statistical significance was set at 5% and 10%. 
Evaluation of the contributions of cardiovascular risk factors  
To evaluate and compare the overall and partial effects of cardiovascular risk factors 
present at the time of the haematological diagnosis, Mann–Whitney and multivariate binary 
logistic regression tests were performed in the cases of the presence or absence of thrombotic 
complications: cerebrovascular (ischaemic stroke or a TIA), cardiovascular (MI) and venous 
thrombotic events (deep venous thrombosis or a pulmonary embolism). In this context, 
besides the investigated cardiovascular risk factors (hypertension (> 140/80 mmHg), 
hyperlipidaemia (hypercholesterolaemia or hypertriglyceridaemia or both), tobacco use, 
diabetes mellitus and obesity (BMI > 30 kg/m2)), the conventional risk factors (an age over 60 
and prior thrombosis), the JAK2 V617F mutation and the therapy of the patients (hydroxyurea 
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and aspirin) were additionally involved and compared. Statistical significance was set at 5% 
and, in view of the number of enrolled patients, statistical significance was also considered 
and set at 10%. To evaluate and compare the probability of the thrombosis-free survival of (a) 
ET patients without cardiovascular risk factors and patients with at least one cardiovascular 
risk factor, and (b) ET patients with at most one cardiovascular risk factor and patients with 
two or more cardiovascular risk factors, the Kaplan–Meier method was used followed by the 
log-rank test (Mantel–Cox) 21. Statistical significance was set at 5% and 10%. 
Evaluation of the IPSET model on the thrombosis-free survival of the patients 
The patients were subgrouped and the main clinical characteristics were compared on 
the basis of a 3-tiered prognostic model, IPSET 14. In this model, patients were stratified into 
IPSET low, intermediate and high risk categories based on the results of multivariable 
analysis-derived hazard ratios (HRs): patients age > 60 years (HR = 1.5; 1 point), a history of 
thrombosis (HR = 1.9; 2 points), cardiovascular risk factors (HR = 1.6; 1 point), and JAK2 
V617F (HR = 2.0; 2 points) 14. According to these results, patients with < 2 points could be 
classified in the low-risk group. In this model, an intermediate-risk group is introduced for 
patients with 2 points. The IPSET high-risk risk group comprising patients with > 2 points 14. 
For the clinical utility of IPSET from the aspect of the thrombosis-free survival of the 
patients, the IPSET subgroups were compared by the Kaplan–Meier method followed by the 
log-rank test (Mantel–Cox) 21. 
 
3.3. LABORATORY METHODS 
Samples for genetic analyses were collected from the DNA bank at the Institute of 
Medical Genetics, University of Szeged, based on the information on the ET patients 
diagnosed at the 2nd Department of Internal Medicine, University of Szeged, between 1999 
and 2014.  
From EDTA-stabilized peripheral blood samples, DNA was isolated and screened for 
the JAK2 V617F mutation as the part of diagnostic protocol with an allele-specific PCR 
method 22. In the cases of patients whose haematological diagnosis was established before the 
JAK2 V617F mutation became an officially recommended part of the diagnostic protocol, 
their samples were collected retrospectively and also analysed. The samples of the JAK2 
V617F(-) patients were suitable for MPL mutation (W515L, W515K, W515R, W515A and 
S505N) analyses by allele-specific PCR reactions and subsequent agarose gel electrophoresis. 
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PCR reactions were performed and the MPL W515L and W515K mutations were assessed as 
described by Bergamaschi et al. 23. Allele-specific primers for MPL W515R, for MPL W515A 
and for MPL S505N were designed to detect futher mutations of exon 10 of the MPL gene and 
PCR reactions and subsequent agarose gel electrophoresis were performed as described by the 
Hungarian National Blood Transfusion Service Laboratory, Budapest, Hungary. This method 
was used with their agreement. As a control experiment, samples were sequenced by an 
automated single capillary genetic analyser (ABI PRISM 310, Applied Biosystems, Life 
Technologies). To assess the CALR mutation status, a fragment analysis with FAM-labelled 
primers were performed on the samples of patients who had JAK2 V617F(-) essential 
thrombocythaemia. To characterize the types of CALR mutations, bidirectional Sanger 
sequencing was performed with the BigDye 3.1 Terminator Cycle Sequencing Kit (Applied 
Biosystems). CALR mutation analyses were possible in a close cooperation with the 1st 
Department of Pathology and Experimental Cancer Research, Semmelweis University, 
Budapest, Hungary. 
 
4. RESULTS 
 
4.1. THE CONTRIBUTION OF THE LEUKOCYTE COUNT ON SUBSEQUENT THROMBOTIC 
COMPLICATIONS  
On the basis of database 99-11, the median leukocyte count measured at the 
haematological diagnosis was 9.4 giga/L (range: 4.5-34.0 giga/L). Separately, in the cases 
when no thrombotic complications were observed during the follow-up period, the median 
leukocyte count was 9.4 giga/L (range: 4.5-28.6 giga/L), while in the cases when subsequent 
thrombotic complications were observed in the follow-up period, the median leukocyte count 
was 9.1 giga/L (range: 5.7-34.0 giga/L). In detaily, the patients who had cerebrovascular 
complications in the follow-up period (stroke or TIA) had a median leukocyte count of 7.5 
giga/L (range: 5.7-13.3 giga/L) at the time of ET diagnosis. In the cases of cardiovascular 
complications (MI), the patients had a median leukocyte count of 10.4 giga/L (range: 9.3-16.7 
giga/L), while the median leukocyte count in the cases of the patients who had subsequent 
venous thrombotic events was 16.7 giga/L (range: 10.1-34.0 giga/L). 
 As concerns the possible contribution of the leukocyte count at the time of ET 
diagnosis in the prediction of subsequent thrombotic complications, the optimal regression 
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gave 9.15 giga/L as the cut-off value of the leukocyte count which had statistically the most 
balanced predictive value. 
 In the comparison of the two subgroups which differed in the presence or absence of 
major thrombotic complications in order to explore the overall and partial effects of the 
leukocyte count cut-off value 9.15 giga/L, Mann–Whitney univariate tests and multivariate 
binary logistic regression analyses revealed only (univariate: p=0.813; multivariate: relative 
risk: 0.528, 95% CI 0.156-1.785; p=0.304) non-significant tendencies. The analysis of the 
contribution of leukocytosis (at a median leukocyte count of at least 11.1 giga/L) also led to 
non-significant results (univariate: p=0.525; multivariate: relative risk: 0.325, 95% CI 0.071-
1.487; p=0.147).  
Similarly, a significant difference was not observed in connection with the Kaplan–
Meier curves followed by the log-rank test (Mantel–Cox) in the comparison of the 
thrombosis-free survival of the patients who suffered and did not suffer thrombotic 
complications in the follow-up period with a leukocyte count cut-off of 9.15 giga/L (p=0.728) 
or with a median leukocyte count of 11.1 giga/L (p=0.478). 
 
4.2. THE PRESENCE OF THE JAK2 V617F, MPL AND CALR MUTATIONS AND THEIR 
CLINICOHAEMATOLOGICAL ROLES  
 
The JAK2 V617F mutation 
From database 99-11, JAK2 V617F(+) cases were detected in 61 (60.39%) patients. 
The comparison of the JAK2 V617F(+) and JAK2 V617F(-) patients by means of univariate 
analysis revealed no statistically significant association with the thrombotic complications 
(p=0.651) or with the separately analysed cardiovascular events (p=0.849), cerebrovascular 
events (p=0.558) or venous thrombotic events (p=0.849). An age > 60 years (p=0.060) and 
the median platelet count (p=0.042), the haemoglobin level (p=0.000), the red blood cell 
count (p=0.000) and the haematocrit (p=0.000) were significantly different in the JAK2 
V617F(+) and JAK2 V617F(-) groups. The median white blood cell count was not 
significantly higher in the JAK2 V617F(+) group than in the JAK2 V617F(-) group (p=0.401). 
At the haematological diagnosis of ET, a significantly higher number of hepatomegaly cases 
were observed in the JAK2 V617F(+) group than in the JAK2 V617F(-) group (p=0.045). 
However, the numbers of splenomegaly cases (in the JAK2 V617F(+) group vs. in the JAK2 
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V617F(-) group (p=0.973)), and hepatosplenomegaly cases (in the JAK2 V617F(+) group vs. 
in the JAK2 V617F(-) group (p=0.383)) did not show a significant difference 24. 
Multivariate binary logistic regression analysis on the subsequent thrombotic events after 
the diagnosis of ET revealed a significant partial effect of the prior thrombotic events (relative 
risk: 2.876, 95% CI 0.847-9.774; p=0.090), but a significant association was not observed 
between the JAK2 V617F mutation status (relative risk: 1.297, 95% CI 0.395-4.258; p=0.668), 
an age over 60 years (relative risk: 0.981, 95% CI 0.316-3.048; p=0.974) and the probability 
of subsequent thrombotic complications 24. 
 To estimate the contribution of the presence of the JAK2 V617F mutation on the 
probability of thrombosis-free survival during the follow-up period, the JAK2 V617F(+), low-
risk patients, the JAK2 V617F (+) high-risk patients, the JAK2 V617F (-) low-risk patients and 
the JAK2 V617F(-) high-risk patients were compared via the Kaplan–Meier curves and the 
log-rank test (Mantel–Cox), which revealed only non-significant differences, p=0.548 24. 
 The MPL and CALR mutations 
The MPL W515L/K/R/A, and S505N mutations were analysed on the basis of database 
99-11. In the cases of 4 JAK2 V617F(-) ET patients, DNA was not available for further 
analyses, and thus samples from 36 JAK2 V617F(-) ET patients could be used for MPL 
analyses. The allele-specific PCR and the subsequent sequence analyses revealed MPL 
W515L mutation positivity in 4 samples, while for the MPL W515/K/R/A and S505N 
mutations the DNA tests of the 36 JAK2 V617F(-) patients were negative 24. 
As regards a comparison of the JAK2 V617F(-) patients with or without the MPL 
W515L mutation, the difference in the numbers of MPL W515L(+) and MPL W515L(-) 
patients did not allow a meaningful statistical analysis, but the MPL W515L mutation was 
predominantly observed in female patients, and in older patients (median age: 70 years). The 
MPL W515L(+) patients exhibited a higher median platelet count at the initiation of the 
haematological observation (845.5 giga/L) than that of the JAK2 V617F(-), MPL W515L(-) 
patients (585 giga/L). The comparison of the numbers of prior and follow-up thrombotic 
events interestingly revealed a lower number of thrombotic complications in the JAK2 
V617F(-), MPL W515L(+) patients than in the JAK2 V617F(-), MPL W515L(-) patients 24. 
CALR type-1 and type-2 mutation analyses were possible in the cases of 22 JAK2 
V617F(-) and MPL W515L(-) ET patients where sufficient DNA was available for further 
genetic investigations. The allele-specific PCR and the subsequent sequence analyses revealed 
positivity only in the case of the CALR mutation type-2 (c.1154_1155insTTGTC), which was 
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detected in 3 samples. These patients were relatively young (median age: 49 years), with a 
higher median platelet count (951 giga/L) and with a lower number of thrombotic 
complications in the follow-up period as compared with the JAK2 V617F(-), MPL W515L(-) 
or the JAK2 V617F(-), MPL W515L(+) patients 24. 
 
4.3. THE CONTRIBUTIONS OF THE CARDIOVASCULAR RISK FACTORS TO SUBSEQUENT 
THROMBOTIC COMPLICATIONS  
The univariate and multivariate statistical analyses based on database 99-11 revealed a 
significant overall association between the thrombotic complications and a high blood 
pressure (univariate p=0.092; multivariate: relative risk: 2.174, 95% CI 0.531-8.899; p=0.280) 
and partial and overall effects in the case of hyperlipidaemia (univariate: p=0.011; 
multivariate: relative risk: 3.511, 95% CI 0.797-15.470; p=0.097). Tobacco use (univariate: 
p=0.545; multivariate: relative risk: 0.971 95% CI 0.193-4.890; p=0.971), diabetes mellitus 
(univariate: p=0.965; multivariate: relative risk: 0.735 95% CI 0.063-8.555; p=0.806) and 
obesity (univariate: p=0.634; multivariate: relative risk: 0.835, 95% CI 0.175-3.990; p=0.821) 
were not associated with a risk of subsequent thrombosis. The presence of one cardiovascular 
risk factor (univariate: p=0.096) or two or more cardiovascular risk factors (univariate: 
p=0.025; multivariate: relative risk: 2.862, 95% CI 0.852-9.614; p=0.089) significantly 
increased the risk of thrombotic complications. 
In this context, the JAK2 V617F mutation, and the well-known conventional risk 
factors were also investigated. Univariate and multivariate statistical analyses revealed non-
significant tendencies, from the aspects of the presence of the JAK2 V617F mutation 
(univariate: p=0.651; multivariate: relative risk: 1.083, 95% CI 0.301-3.891; p=0.903) and an 
age over 60 years (univariate: p=0.877; relative risk: 0.815, 95% CI 0.217-3.067; p=0.763). 
However the partial effect of the reported previous vascular events in the possible occurrence 
of further thrombosis was significant (univariate: p=0.066; multivariate: relative risk: 2.406, 
95% CI 0.686-8.437; p=0.170). 
The administered therapy was incorporated in the analysis in order to consider its 
potential influence on the thrombotic events in the follow-up period. Although differences 
could be observed between the patients treated with antiplatelet (univariate: p=0.730) or 
cytoreductive therapy (univariate: p=0.319) in the two subgroups, depending on the presence 
or absence of major thrombotic events, but these differences were not significant.  
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To compare the thrombosis-free survival of the patients in the presence or absence of 
the investigated cardiovascular risk factors, Kaplan–Meier curves and log-rank tests (Mantel–
Cox) were utilized, which resulted in a significant difference between the thrombosis-free 
survival of the ET patients without cardiovascular risk factors (n=47) and those with at least 
one cardiovascular risk factor (n= 54) (p=0.011). A significant difference was also observed 
between the ET patients with at most one cardiovascular risk factor (n=77) and those with two 
or more cardiovascular risk factors (n=24) (p=0.002) 25 . 
 
4.4. ANALYSES OF THE NEUROLOGICAL AND CARDIOLOGICAL CHARACTERISTICS    OF 
THE CEREBROVASCULAR AND CARDIOVASCULAR COMPLICATIONS, AS THE MOST SEVERE 
THROMBOTIC COMPLICATIONS OF ET PATIENTS 
Cerebrovascular complications 
In 2012, database 99-11 revealed cerebrovascular complications (stroke/TIA/ 
vertebrobasilar insufficiency) in 4 males and 7 females with a median age of 67 years [range: 
45-82 years]). The median platelet count at hematological diagnosis was 658 giga/L [range: 
514-1157  giga/L], while at the time of the cerebrovascular events it was 450  giga/L [range: 
320-885  giga/L]. All of the 11 analysed cases were JAK2 V617F(+). Mostly TIAs and/or 
minor strokes were noted. In most cases (8/11; 73%), the brain imaging modalities (skull CT 
and/or MRI) revealed periventricular and/or subcortical and/or basal ganglia lacunes or 
infarcts or confluent chronic white matter ischaemic lesions in all cerebral arterial regions. 
There were hardly any infratentorial lesions. Atrophy with diverse degrees of severity was 
frequently seen (7/11; 64%). Mainly large infarcts were detected in the middle and posterior 
arterial regions in 4 patients, 3 of whom exhibited posterior watershed-type infarcts. In one, 
patient with a 665 giga/L platelet count, a haemorrhagic transformation of a large parieto-
occipital infarct was noted, without clinical deterioration. In 2 cases, the stroke complication 
itself drew attention to the presence of the underlying ET. Recurrent stroke or a 
vertebrobasilar insufficiency were seen despite the ongoing antiplatelet and cytoreductive 
therapy. No correlation was found between the platelet count and the stroke type or 
occurrence of stroke, although supratentorial lacunar infarcts and chronic white matter lesions 
predominated. It is important to note that most patients (7/11; 64%) displayed at least two or 
more serious conventional vascular risk factors. It could be suggested that these could have 
influenced both the clinical course and the morphological alterations seen on brain imaging 26.  
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Cardiovascular complications 
Detailed analyses on the cardiovascular complications based on database 99-14 
revealed 7 ET patients (3 males and 4 females with a median age of 61 years [range: 38-76 
years]) who suffered MI during the haematological follow-up period. With the exception of 
one case, the ET haematological diagnosis and the presence of the MI occurred within 12 
months. The median platelet count at hematological diagnosis was 647 giga/L [range: 562-732 
giga/L], while at the onset of MI it was 630 giga/L [range: 346-1190 giga/L]. Four (57.1%) of 
the analysed 7 cases were JAK2 V617F(+). Most of the patients (85.7%) displayed at least one 
serious conventional vascular risk factor. The coronary angiography findings revealed ST 
segment elevation MI (STEMI) in 4 cases (1 subacute STEMI, 2 anterior STEMI and 1 
inferior STEMI), while non-STEMI (NSTEMI) was observed in 3 patients. Stent implantation 
had been performed in most of the patients. In 5 cases, significant stenosis of the coronary 
arteries required percutaneous coronary intervention with a stent implantation. One patient 
had undergone a coronary artery bypass graft operation. Recanalization proved unsuccessful 
in one case. Reccurrent MI events were not observed in the follow-up period. We found no 
correlation between the platelet counts and the MI type or the degree of stenosis. 
 
4.5. THE IPSET MODEL AND THE THROMBOSIS-FREE SURVIVAL OF THE PATIENTS 
 
Patients (based on database 99-14) were subgrouped and the main clinical 
characteristics were compared on the basis of the IPSET score 14. From the data on the current 
cohort, the clinical characteristics of an intermediate-risk group of patients could be clearly 
differentiated from those of the low- and high-risk groups. 
To compare the thrombosis-free survival of the patients categorized in the IPSET low-risk, 
IPSET intermediate-risk and IPSET high-risk groups, the Kaplan–Meier method was applied, 
followed by the log-rank test (Mantel–Cox), which resulted in significant differences between 
the different IPSET groups (p=0.002) 27.  
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5. SUMMARY AND CONCLUSIONS 
 
1. The reported incidence of thrombohaemorrhagic events in ET patients lies in the 
interval 11-25% 6-8. Thrombotic events appear more commonly than haemorrhagic 
ones and among the thrombotic complications arterial thrombosis is more often 
observed than venous thrombosis 6. In the current cohort in the period 1999-2014 
retrospectively, the numbers of major thrombotic events that occurred previously were 
30.32% and during the follow-up period 14.83% were evaluated. Arterial 
complications (80%) predominating over venous ones (20%).  
 
2. The current goal of ET therapy is to prevent thrombohaemorrhagic complications 28. 
The haematological management strategy is based on risk-oriented recommendations, 
according to which the patients are stratified into low- and high-risk subgroups by the 
absence or presence of either an age > 60 years or a history of thrombosis 7, 19, 20. 
However, recent publications suggest that this two-categorical classical risk 
stratification may not be sufficiently sensitive. The impact of other additional risk 
factors on thrombosis, such as leukocytosis, JAK2 V617F mutation and the classic 
cardiovascular risk factors has recently been under active investigation 6, 11-16, 29.  
 
a) Some literature studies suggest the contribution of the leukocyte count and 
leukocytosis at the diagnosis of ET to subsequent thrombotic events, but other 
reports did not verify this 30-35. Our findings on the current study population 
likewise did not confirm this suggestion. The leukocyte count cut-off value at the 
time of ET diagnosis relating to the current patient population (9.15 giga/L) was 
not associated with a higher risk of subsequent thrombotic complications either; 
likewise, the leukocytosis analysis did not indicate any potential association. 
The leukocyte count measured at the time of the ET diagnosis, is probably not a 
sufficiently sensitive marker; its contribution is biologically plausible, but 
clinically uncertain.  
 
b) The presence of the JAK2 V617F, MPL and CALR mutations in the current patient 
population was analysed. The revealed occurrence of these mutations and their 
impact on the clinicohaematological findings were in line with the relevant 
literature In ET, approximately 50-60% of the patients possess the JAK2 V617F 
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mutation 6, 14. In the current study population, 60-69.7% of the patients were found 
to harbour the mutation. It has been reported that JAK2 V617F(+) ET patients are 
older, have a higher rate of thrombohaemorrhagic complications, higher 
hemoglobin levels and a higher leukocyte counts than JAK2 V617F(-) patients 36-
40
. In the current study, the JAK2 V617F(-) cases differed significantly from the 
JAK2 V617F(+) cases from the aspects of the platelet, haemoglobin, red blood cell 
and haematocrit counts and hepatomegaly. However, the presence of the mutation 
was not associated statistically significantly with an increased risk of thrombosis: 
only non-significant tendencies were observed. In the IPSET risk stratification 
model, the predictive potential of the JAK2 V617F mutation on subsequent 
thrombosis was incorporated, and promising results were reported 14. However it is 
important to note that the 2015 update on the diagnosis, risk stratification and 
management of ET does not provide a clear-cut standpoint as concerns the 
predictive role of the JAK2  V617F mutation in thrombotic complications 28.  
 
 In JAK2 V617F(-) cases, other mutations have been investigated from the aspect 
of their influence in thrombotic complications, e.g. the MPL mutations (MPL 
W515L, MPL W515K, MPL W515R, MPL W515A, and MPL S505N)  9, 41-45.         
In ET, the most commonly detected (1-5%) MPL mutations are the W515L/K 
mutations 28, 46-48. In current study population, genetic analysis of the JAK2 
V617F(-) cohort revealed a 3.96% incidence of the MPL W515L mutation. It has 
been reported that MPL mutations may be associated with higher platelet counts, 
older age and a female predominance 43, 49. In current study the patients who 
displayed the MPL W515L mutation were also older, were predominantly female 
and had higher platelet counts as compared with the JAK2 V617F(-), MPL 
W515L(-) patients. In the cases of JAK2 V617F(-) and MPL W515L(+) patients, we 
could observed lower numbers of thrombotic complications as compared with the 
JAK2 V617F(-) and MPL W515L(-) patients. 
 
In JAK2 V617F-unmutated ET, the presence of CALR type-1 or type-2 somatic 
mutations has recently been identified with an estimated frequency of 15-32% 17, 
50, 51
. Genetic analysis of our JAK2 V617F(-) cohort revealed CALR type-2 
mutation positivity in 3 cases. It has been reported that a more indolent clinical 
course, with a younger age and a lower leukocyte count, but a higher platelet count 
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and a decreased risk of thrombosis, may be observed among patients with CALR 
mutations 17, 50, 51. In the current study the patients who harboured the CALR type-2 
mutation were relatively young and had a lower median leukocyte count and a 
higher median platelet count at diagnosis, and in these cases a lower number of 
thrombotic complications were observed. 
 
c) During this single-centre analysis, we evaluated the roles of cardiovascular risk 
factors in the major thrombotic complications of ET. Our results demonstrated that 
the most important cardiovascular risk factors contributing to an enhanced 
thrombotic tendency were high blood pressure and hyperlipidaemia. The presence 
of one or two or more cardiovascular risk factors significantly increased the risk of 
thrombosis during the follow-up period of the ET patients. The thrombosis-free 
survival was also significantly different between patients without cardiovascular 
risk factors and those with at least one cardiovascular risk factor, and between 
patients with at most one cardiovascular risk factor and those with two or more 
cardiovascular risk factors. Based on these results the contribution of 
cardiovascular risk factors as newly suggested additional risk factors to the 
subsequent thrombotic complications of ET was confirmed in indicating the 
importance of the identification and consideration of cardiovascular risk factors in 
a more accurate thrombosis risk-guided management. 
 
3. As concerns the clinical characteristics of the neurological and cardiological 
compliations of ET, from the aspect of the cerebrovascular complications in the 
current cohort, mostly TIAs and/or minor strokes were observed within a wide range 
of time during the course of ET. Recurrent stroke or a vertebrobasilar insufficiency 
were seen despite the ongoing antiplatelet and cytoreductive therapy. We did not 
detect a correlation between the platelet count and the stroke type or the occurrence of 
stroke. Most patients displayed at least two or more serious conventional vascular risk 
factors, which could be suggested to have influenced both the clinical course and the 
morphological alterations seen on brain imaging.  
 
As regards cardiovascular complications, both STEMI and NSTEMI were present. 
Interestingly, most of the MI complications occurred within 12 months after the 
haematological diagnosis of ET. No recurrent MI was subsequently observed during 
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the follow-up period. No correlation with the platelet count was identified. Most 
patients displayed at least one conventional vascular risk factor. 
Our findings lead us to suppose that the early diagnosis and percutaneous coronary 
intervention and the personalized management of the patient’s cardiovascular risk 
factors may greatly facilitate the prevention of these further vascular events. The 
importance of the close cooperation of the haematologist and other specialists in the 
field of vascular medicine is emphasized. 
 
4. The new IPSET score system published by Barbui et al. in 2012 incorporates the 
predictive potential of the cardiovascular factors and the JAK2 V617F mutation 14. In 
addition to the classical two-categorical risk assessment, it includes an intermediate-
risk group of patients who were previously not clearly identified 14. The clinical value 
of the IPSET model, especially as concerns the thrombosis-free survival of the 
patients, was examined for the first time in a cohort of ET patients diagnosed in a 
single Hungarian haematological centre. Significant differences were observed in the 
thrombosis-free survival of patients stratified into low, intermediate and high-risk 
IPSET subgroups, suggesting that this score system provides more information than 
the conventional thrombosis risk assessment. However, further prospective 
investigations are required to establish the potential advantages of the IPSET score 
system in everyday practice, and to determine whether cytoreductive treatment is 
necessary in the IPSET intermedier-risk subgroup. In the relevant literature up to  
September 2014, only one external validation result is available on IPSET 52. That 
analysis too demonstrated the significant differences in the cumulative thrombosis-free 
survival of ET patients classified by IPSET 52. 
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